Cite
Lu H, Lu W, Zhu Y, et al. Auranofin Has Advantages over First-Line Drugs in the Treatment of Severe . Antibiotics (Basel). 2020;10(1)doi: 10.3390/antibiotics10010026.
Lu, H., Lu, W., Zhu, Y., Wang, C., Shi, L., Li, X., Wu, Z., Wang, G., Dong, W., Tan, C., & Liu, M. (2020). Auranofin Has Advantages over First-Line Drugs in the Treatment of Severe . Antibiotics (Basel, Switzerland), 10(1), . https://doi.org/10.3390/antibiotics10010026
Lu, Hao, et al. "Auranofin Has Advantages over First-Line Drugs in the Treatment of Severe ." Antibiotics (Basel, Switzerland) vol. 10,1 (2020). doi: https://doi.org/10.3390/antibiotics10010026
Lu H, Lu W, Zhu Y, Wang C, Shi L, Li X, Wu Z, Wang G, Dong W, Tan C, Liu M. Auranofin Has Advantages over First-Line Drugs in the Treatment of Severe . Antibiotics (Basel). 2020 Dec 30;10(1). doi: 10.3390/antibiotics10010026. PMID: 33396878; PMCID: PMC7823847.
Copy
Download .nbib